Survodutide vs Tirzepatide
How Survodutide and Tirzepatide compare on research category, evidence tier, regulatory status, and reported side effects.
The verdict
Tirzepatide is FDA-approved as Mounjaro and Zepbound; survodutide is still in trials, and that gap matters more than the mechanism difference. They pair GLP-1 with different partners: tirzepatide with GIP, survodutide with glucagon, which is aimed at raising metabolic rate rather than only cutting appetite. Survodutide's Phase 3 topline came in around 16.6% at 76 weeks, under what tirzepatide has reported, so it reads as one to watch rather than one with a record.
Survodutide is Boehringer Ingelheim's dual agonist (GLP-1 + glucagon), a competitor to Retatrutide. Stronger fat-burn signal than the GLP-1-only drugs because it activates glucagon, which boosts metabolic rate. Phase 2 data is promising. Once-weekly.
Tirzepatide is the prescription weight-loss drug sold as Mounjaro (diabetes) or Zepbound (weight loss). It hits two appetite-control receptors at once. Most users lose 15-20% of body weight over several months. One injection per week.
Which one should you pick?
Pick Survodutide if users plateaued on glp-1-only drugs or people targeting >15% body weight loss.
Pick Tirzepatide if users who couldn't tolerate semaglutide or metabolic-syndrome adults under provider guidance.
Still torn between Survodutide and Tirzepatide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.
Want the latest evidence updates?
Drop your email and we'll send you the one-page checklist for vetting any peptide before you trust a vendor or a forum: what to verify, the red flags, and the questions to ask a licensed provider. No card.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.